版权说明:本文档由用户提供并上传,收益归属内容提供方,若内容存在侵权,请进行举报或认领
文档简介
How
are
life
sciencesengineering
leadersbalancingspeed,agility,and
compliance,in
anageofdisruption?Life
Sciences
EngineeringandR&D
Pulse
Report2026RepoΓt
scopeThisreportpresentsthekeyinsightsfromtheLifeSciences
Engineering
Pulse2026,part
of
ourbroader
cross-sector
Engineering
&
R&D
Pulse.It
is
based
on
a
global
survey
of200senior
lifesciencesleadersfromlargeorganizationsacross
pharmaceuticals,biotechnology,medicaldevices,
anddigitalhealth.Respondentsareseniordecision-makersresponsible
forengineeringacrosstheentireproductlifecycle
–
fromearlyR&Danddesigntoregulatoryandquality
compliance,industrialization,supplychainoperations,andcommercialization.Thequotesandcasestudiesincludedareillustrative
innature,maybedrawnfrompubliclyavailablesources,anddonotnecessarilyreflecttheviewsor
statementsofsurveyrespondents.ReportdemographicsPharmaceuticalsMedTechBiotechnologyLabautomationandresearchtoolsDigital
health
and
Software-as-a-Medical
Device(SaMD)ThedatainthereportwasgatheredbytheCapgeminiResearchInstitutein
August2025via
asurveyofexecutivesatorganizationswithmorethan$1billioninannualrevenue.Thisdataisfromasubsetof200LifeSciencesC-levelandSeniorLeadershipacrossNorth
America,Europe,APAC,andtheMiddleEast.Subsectorbreakdown:Fewindustriessharethelifesciences'weightofresponsibility.EveΓydΓugappΓoved,eveΓydevicedeployed,eveΓytheΓapydevelopedhasadiΓectbeaΓingonhuman
health
and
quality
of
life.Yet
the
oΓganizations
entΓusted
with
thatΓesponsibility
aΓeopeΓating
in
one
of
the
most
complex
enviΓonments
inΓecent
memoΓy
-one
defined
by
geopoliticalvolatility,intensifyingglobalcompetition,acceleΓatingtechnologicaldisΓuption,stΓuctuΓalcostandtime
pΓessuΓes,and
an
unpΓecedented
pace
of
technological
change
dΓiven
by
AI.The
question
this
report
asks
is
a
simple
but
urgent
one:aΓe
life
sciences
oΓganizations
pΓepaΓedto
meet
this
moment?Based
on
the
evidence
gatheΓed
fΓom
senioΓexecutives
acΓoss
the
sectoΓ,
theansweΓisthatwhileambitionishigh,thegapbetweenstΓategicintentandopeΓationalΓeadinessΓemains
significant-and
the
window
to
close
it
is
naΓΓowing.Our
aim
was
threefold:to
undeΓstand
the
foΓces
shaping
the
industΓy’s
stΓategic
agenda;tobenchmaΓk
wheΓe
oΓganizations
cuΓΓently
stand
in
theiΓengineeΓing
tΓansfoΓmation
jouΓneys;andtoidentifythesolutions,models,andtechnologiesthatleadingoΓganizationsaΓedeployingtostay
competitive.In
doing
so,we
sought
not
only
to
suΓface
individual
challenges,but
to
pΓovide
acollective
view-one
that
allows
leadeΓs
to
benchmaΓk
theiΓpΓogΓess,leaΓn
fΓom
peeΓs,and
findshaΓed
solutions
to
shaΓed
pΓoblems.What
you
willlearnA
pΓactical
lens
on
the
foΓcesdΓivingchange
-andthesolutionsleading
oΓganizations
aΓeadopting.KeyfindingsWhatwefoundwasasectorthatis
simultaneouslybrimmingwithopportunityandburdenedbychallengesthatthreatencompetitiveness,resilience,and
innovation.Organizations
are
aligned
on
vision
–
but
not
yet
prepared
to
deliver
at
scale.The
fi∩di∩9s
ofthis
ΓepoΓt
deliveΓ
a
cleaΓ
messa9e:
theco∩veΓ9e∩ce
of9eopolitical
volatility,
acceleΓati∩9
AI
adoptio∩,
deepe∩i∩9
tale∩tshoΓta9es,
a∩dsustai∩ed
cost
a∩d
timeli∩epΓessuΓes
is
fu∩dame∩tally
Γeshapi∩9
life
scie∩ces
e∩9i∩eeΓi∩9.These
foΓces
aΓe
cΓeati∩9
a∩
impoΓta∩t
9ap
betwee∩
stΓate9ic
ambitio∩
a∩d
executio∩
Γeadi∩ess—o∩e
that
the
i∩dustΓy
ca∩
∩o
lo∩9eΓ
a阡oΓd
to
i9∩oΓe.”NirliptaPandaVicePresidentandGlobalHeadofIndustry
LifeSciences|
CapgeminiEngineeringnirlipta.panda@TheurgencyoflifesciencestransformationisrealThepressuresreshapingthelife
sciencessectorGeopoliticaluncertaintyemergesasamajorconcern,with53%oflifesciencesexecutivesnamingitasa
majorthreatand57%acknowledginggapsintheirreadinesstomanageitsimpact.Fromtariffsandtrade
barrierstosovereigntymandatesandglobalconflicts,leadersfaceafragmentedworldwherecross-bordercollaborationisharder.Supplychainfragilityreinforcesthisvulnerability:halfofrespondentssee
disruptions
–including
raw
material
scarcity
–as
a
major
threat,
and47%say
they
are
not
adequatelypreparedforthem.Talentshortages,particularlyincriticaldisciplinessuchasengineering,digital,andAI,areanotherpersistent
pressure
point.Nearly
half,43%,identify
skills
scarcity
as
a
significant
threat,and
almost
asmanyacknowledgetheyareunpreparedtofillthesegaps.Compoundingthisistherapidaccelerationof
AItechnologies,includinggenerativeandagenticAI.Halfof
respondentsseeAIasamajorthreat,butalsoanopportunity,thoughrespondentsarelargelyconfidentin
theirpreparednessforthecomingAIwave,atleastmoresothanotherchallenges.Finally,longstanding
concerns
loom
large.Cost
rises(82%report
increases
over
thelastthree
years)andlengtheninginnovationtimelines(91%saydevelopmentcycleshavelengthened)areseenasproblemsinneedofsolutions.Developmenthorizonscan
be8-10years,3-4of
which
are
dedicated
to
regulatory
processes.90%say
that,to
stay
competitive,they
need
to
reduce
time
spent
on
design
and
development
by5-15%.Thatwillneedtoincludemoreefficiencyincompliance.Allthisisagainstabackdropofrisingglobalcompetition,withforecastsexpecting35%of
FDA
approvals
for
drugs
to
originate
in
China
by2040,up
from
just5%today.[1]Source:
[1]
Morgan
Stanley,“The
Innovation
Boom
in
China
Biotech”,
September2025.Withoutsignificantcostreductions,
ourorganizationrisksbecominguncompetitiveagainststartupsand
emergingmarketplayers
withinthe
nextfive
years.Werisklosingsignificantmarketshare
tostartupsandemergingmarketplayers
withinthenextfive
years,if
wefailtoinnovatefaster.*
Percentageofrespondentsstronglyagreeingwith
thestatementsabove.**lnlightofthesechallenges,whataΓelifesciences
leadeΓs’
stΓategic
pΓioΓities?Compliancefirst
–butagilityistherealdifferentiator.Perhapsunsurprisingly,improvingregulatorycomplianceclearlyleadstheway:65%of
respondentshighlightitsimportance,and45%identifyitastheirtopstrategicconcern.Agilityemergesasthenextkeyareaofattention,with18%sayingitwastheirtoppriority,
and52%sayingitwastheirsecondpriorityaftercompliance.Thatunderscorestheneedfor
faster,moreadaptiveoperations,withmoreflexibletalentpoolsandsupplychains,thatcan
withstandglobalvolatility.Beyondthesetwoareas,companiesrevealedalonglistofstrategicgoalstheyaspiredto.Cost
savings(48%)and
reducing
time
to
market(45%)were
both
high
on
the
agenda.Relatedtothese,48%saidthatembracingdigitaltechnologiestoinnovatewasanimportant
priority.Asaresult,lifesciencesleadersfaceachallengingtime.Tostaycompetitive,theymust
becomemoreagiletothriveinavolatileworld.Theymustalsoreducecostsandshorten
innovationcycles,whileadheringtoregulatory&complianceguidelines
–allwithoutcompromisingsafety.Howcantheydoallofthistogether?Sources:[2]
Takeda
–Press
release,“Changes
to
Fuel
Speed,Competitiveness
and
Future
Growth”,January2026.[3]
Pfizer
–CEO
Letter,Annual
Review2025.Thechangesannouncedtodayarethecatalyst
for
our
nextera,enablingsimplicity,speed
and
efficiency
–without
sacrificingquality
–tohelpus
moveat
pacetobringlife-transformingmedicinestopatients.
”Julie
Kim|CEO-Elect,Takeda[2]We’re
striving
to
increase
the
speed
ofeverythingwedotodrivehigh-quality
innovationtoimprovelives.
”DΓ.AlbeΓtBouΓlaIChairman&CEO,Pfizer[3]How
are
life
sciences
leadersresponding
to
these
challenges?Turningpressure
intoactionHowarelifesciencesleaders
attemptingtobuildagile,resilient
organizations,whichcutcostsandcompressinnovationcycles,all
whileensuringcomplianceisstrictlyadheredto?Threedominantareasemergefromthefindings:Shiftingtoglobal
operatingmodelsand
accessingglobaltalentRead
more>Read
more>Read
more>Increasingorganizational
agilityEmbracingAI
and
newtechnologiesHighlights84%areinvestingindigitaltoolstobetter
anticipateshocks79%areimplementingflexibleoperational
systemstodynamicallyscaleproduction71%citelimitedsupplychainflexibility67%struggletoreallocateresourcesIncreasingorganizationalagilityAsmarketconditionsbecomemoreunpredictable
–shapedbygeopoliticalshifts,fluctuatingdemand,andsupplychainfragility
–lifesciencescompaniesareprioritizingagilityitselfasacorestrategiccapability.Manyareacceleratingeffortstobuildmoreflexibleoperating
modelsthatcanrespondquicklyandefficientlytochangingneeds.Agilityisnot
justaboutrespondingtobigchangeslikeawarorapandemic.Itisalsoaboutconstantlyadjustingtheorganizationtoenable
rapid,cost-effectiveinnovation,suchasquicklyscalingupsoftwarecapabilities,orbeingabletodeploynewproductivity-boosting
innovations,likeAIorrobotics,intoexistingprocesses.Nearlyeightintenorganizations(79%)areimplementingflexibleoperationalsystems,includingmodularproductionlines,adaptivestaffing
approaches,andreal-timescheduling,todynamicallyscalecapacityupor
down
in
line
with
demand(Chart3).Such
approaches
also
make
it
easier
totransferorscalecapabilitybetweenfacilitieswhenneedschange.Atthesametime,85%areinvestingindigitaltoolsforscenarioplanning
toanticipateexternalshocks,liketariffsorregulatorychanges,andtomodelimpactsandresponseswithgreaterprecision.We
see
several
examples
of
this,for
example
Joaquin
Duato,Chairman&
CEOof
Johnson&Johnson,hasmadedigitaltransformationacentralplankofhisleadership,deployingpredictiveanalyticsthathavetrimmed
inventorywrite-offsbyanestimated$400million.IncreasingorganizationalagilityAgility
inaction:ManufacturingupgradesatscaleSanofi’sMARS(MES
Accelerated
Roadmap@Sanofi)programis
delivered
incollaboration
withpartners,includingCapgemini[4].MARS
is
a
large-scale
digital
manufacturing
initiative
to
standardizethecompany’sManufacturingExecutionSystem
(MES)globallyandreplace
paper-based
batch
records
with
electronic
ones.Usingastandardized
MESmodelandadvancedtechnologies–including
generative
AItohelpconvert
recipesandworkflowsintodigital
MESconfigurations
–the
programhasdelivered
significantgains.
Thoseincludea
70%reductioninbatchreviewtimeandan80%decreaseinproductiondeviations.MARShasbeendeployedat25manufacturing
sites
and
used
by
more
than4,000
people,
with
aroadmap
targeting52sites
by2027.However,achievingtrueagilityremains
challenging.Two-thirdsofexecutives(67%)reportdifficultyreallocatingresources
–whetherpeople,capital,orassets
–acrossprojectsorgeographicregions,
limitingtheirabilitytopivotinrealtime.Supplychainrigidityisalsoamajorbarrier,with71%citinginsufficientvisibilityorflexibilityacrosssourcinganddistributionnetworks.Internally,organizationalresistanceto
changepersists,with61%ofleadersnotingculturalorstructuralpushbackthatslowsorcomplicatestransformationinitiatives.Anagileorganizationrequires
joined-updigitalsystemsacrosssilosand
supplychains,data-drivenintelligence,standardization,modularinfrastructureandacollaborativeculture.Whileagilityisastrategicobjectiveinitsownright,withitsowninternalinvestmentdemands,its
successwillalsodependondigitaltechnologiesandflexibleglobaloperatingmodels
–whicharethesubjectofthefollowingsections.Source:[4]
Siemens
–Corporate
blog,“Driving
Pharma
Manufacturing
Excellence:Sanofi,Capgemini
and
Siemenson
Scaling
MES
with
Generative
AI”,September2025.IncreasingorganizationalagilityAgility
inaction:Real-timemonitoringforagileoperationsA9lobalbiotech&dia9∩osticsleadeΓ,
woΓki∩9with
Cap9emi∩ia∩dotheΓ
paΓt∩eΓs,istΓa∩sfoΓmi∩9ma∩ufactuΓi∩9opeΓatio∩sthΓou9h
a
cloud-based
i∩dustΓialdataplatfoΓm,
whiche∩ables
seamlessi∩te9Γatio∩of
opeΓatio∩ala∩de∩teΓpΓisedataacΓoss
9lobal
sites.
ThepΓojectΓeplaces
fΓa9me∩teddatasiloswithasi∩9le,co∩textualized
souΓceoftΓuth.
ThisdΓamaticallyΓeducesi∩fΓastΓuctuΓecomplexitya∩ddatavolumes,
whileimpΓovi∩9accessibility
foΓ
busi∩essa∩d
e∩9i∩eeΓi∩9teams.Withi∩
lesstha∩
thΓeemo∩ths,
thepΓojecte∩abled
self-seΓvicea∩alytics,
a∩ddi9italmai∩te∩a∩cea∩dpΓedictivemo∩itoΓi∩9usecases
ofcΓiticalassets,
likece∩tΓifu9esa∩d
bioΓeactoΓs.
ThesecapabilitiessuppoΓtfasteΓ
i∩si9hts,impΓovedequipme∩tΓeliability,a∩d
scalable
a∩alyticsdeployme∩t.Highlights74%will
increase
AI
investment
by10%ormoreinthecoming
years72%areconcernedaroundAIreliabilityand
accuracy68%see
AI
benefits
across
the
R&D
lifecycle,
fromconceptdesigntocomplianceto
manufacturing60%EmbracingAIandnewtechnologiesLifesciencesorganizationsareincreasinglyembracingAIalongsideabroadersetofdigitaltechnologiestoaddressspeed,cost,andcomplexity
across
engineering
and
R&D.Thesetechnologiesareseenaspracticalenablerstoimproveproductivity,
strengthencompliance,andincreaseoperationalresilience.Whileadoptionisprogressing,thechallengeliesinscalingandintegrating
thesesolutionseffectivelywithincomplex,highlyregulatedenvironments.Successincreasinglydependsoncombiningtechnologicalinnovationwith
robustgovernance,clearoperatingmodels,andstrongchangemanagement.OrganizationsthatcanmovebeyondpilotstoembedAIand
digitalcapabilitiesend-to-endarebetterpositionedtotranslateambition
intomeasurableimpact.seeAIashighlytransformativeEmbracingAIandnewtechnologiesAIisoneofthebiggestdisruptivethreatsand
biggestopportunities.AI
was
seen
as
having
high
transformative
potential
by60%ofrespondents.Halftotwo-thirdsseeitastransformativeinareasfromresearchtomaintenancesupport(seeA/
inactionattheendof
this
section).58%saw
it
as
having
high
potential
to
address
one
oftheirtopstrategicpriorities:reducingthetimerequiredforcompliance.Indeed,manyexecutivesarealreadyseeingbenefitsfromAIindeliveringstrategicpriorities,withsignificant
AI-relatedimprovementsinproductivity,costreduction,andtimetomarket
(Chart4).Andtherearehighexpectationsofmuchgreaterbenefitsin
the
near
future(Chart5).Life
sciences
leaders
are
optimistic
about
AI.In
fact,94%believe
they
areahead
of
their
peers.This
suggests
that,in
most
companies,there
is
asensethattheyareadvancingwellwithAI,eveniftheydonotrealizethat
theircompetitorsaredoingthesame.Organizationsarealsoquitematureintheiruseof
AI,atleastthetraditional
sort.Most(86%)are
at
the
deployment
stage
–with
live
AI
inlimitedareas,butnotfullyintegratedacrossthebusiness.ForgenerativeAI(GenAI),most(82%)are
in
the
piloting
stage,and
for
agentic
AI,84%
arestillexploringitspotential.Makinghuman-machinecollaborationmorewidelyavailable
allows
engineers
to
accelerate
code
development,increaseinnovationandtackle
skilled
labour
shortages.
”Roland
Busch
|
CEO,
Siemens
AG
[5]Source:[5]
Siemens
–Press
release,“Siemens
and
Microsoft
partner
to
drive
cross-industry
AI
adoption”,October2023.EmbΓacin9Alandnewtechnolo9iesAIinvestmentsettosurge,butchallengesareonthehorizon.Ambitions
are
high.47%say
their
organization
has
allocated
5-20%of
its
total
engineering
and
R&D
budget
to
AI-relatedinitiatives,and
over90%say
that
budget
will
increase
by5-20%over
the
next2-3years(Chart6).But
AI–especially
GenAI–comes
with
challenges.RespondentscitedconcernsaboutAI,rangingfromworries
around
reliability
and
accuracy
of
outputs(72%saying
amajorconcern)tothehighenvironmentalfootprintofGenAIand
agentic
AI(67%),to
their
own
lack
of
internalgovernance
frameworks
for
GenAI
and
agentic
AI(68%).This
is
slowing
adoption(Chart7).Theseareallgenuineconcernstonavigate,butperhapsthe
biggestthreattolifesciencescompaniesisnotembracingAI
andfindingthatitdoesliveuptoitspromise...fortheircompetitors.EmbracingAIandnewtechnologiesActivityResearch&conceptdevelopmentDesign&prototypingSimulation&testingDocumentation,compliance&IPmanagementManufacturing&operationsMaintenance&supportPercentsaying
AIwill
transformin2-3
years49%45%38%58%48%68%AI
opportunities
AI-powered
literatureanalysis,ideagenerationGenerativedesign,
AI-assistedCAD,rapidprototyping,designoptimizationAI-enhancedsimulation,
anomalydetectionAI-generateddocumentation,automatedcompliance
checks,patentlandscape
analysisAI-basedproductionscheduling,computer
vision
forqualitycontrol,predictivesupplychainplanning,autonomousmaterialhandlingAI-baseddiagnostics,predictivemaintenance
planning,intelligentsupportbotsCase
studies
Pfizer
is
using
GenAI
to–often
up
to20,000documentsperdrug.By
enablingnaturallanguage
andvoice-basedqueriesacrossmultiplerepositories,
AIsignificantlyreduces
manualeffort.Thispotentiallysavesupto16,000hoursandcanaccelerateearly-stageresearch.[6]Medtronicisexploringthe
useofgenerative
AItosupportengineersinmedicaldeviceresearchanddevelopment.Thesetechnologieshelpteamsgenerateandevaluatedesignconcepts,accelerate
early-stageengineeringwork,andimproveproductivitybyassisting
–
ratherthanreplacing
–engineeringexpertise.[7]Roche
is
applyingAI-drivenmodelstosupportdrugdiscoveryanddevelopmentbyimprovingmolecularunderstandingandsupportingdata-drivenscientificdecision-making.
Theseapproacheshelpresearchersprioritizetargetsandexplorecomplexbiologicalinteractionsmoreeffectively.[8]A
German
MedTechcompanypartneredwith
Capgeminitoautomatetheextractionofregulatoryrequirements
using
GenAI.Using
largelanguagemodelsandcomputervision,thesolutioninterpretstext,
tables,andimagesfrom
regulatorydocuments,andstandardizesoutputs.Thetoolreducedmanual
effortanderrors,achieving60%resourceoptimizationwhilealsoimprovingcomplianceaccuracy.It
was
designedforscalabilityandhasnow
beenadaptedtoavariety
ofregulatoryentitiesand
cases.Sanofi,Capgemini,andindustryandacademicpartnersareadvancingbiologicsmanufacturingthroughCALIPSO,a€17.5millioninitiativetomodernizebioproduction.Using
advanced
sensors,data
platforms,anddigitaltwins,
theprojectimprovesprocess
monitoring,prediction,and
control.Thiscouldpotentiallyincreaseproductivitytenfold,
while
acceleratingbiologicsdevelopmentandimproving
batchquality.[9]Apharmaceuticalcompanypartneredwith
Capgeminiandsoftware
providerstoimplement
anindustrialDataOpsplatformacrossitssites.
Thisunifyingofdatafor
intelligentassetlifecycle
managementhasincreasedcapacityutilization
by10%,extendedassetlifetimesby20%,and
reducedhuman-errorrisksbyupto80%.Johnson&Johnson
isusingadvancedanalyticsand
AI-enabledplanning
toolstostrengthensupply-chainresilience.Openfulltable
in
browser:
https://capgemini.turtl.co/story/lifesciences-erandd-pulse2026/page/3/10
networks
AIacrosstheLifeScienceslifecyclehelpscientistssearchandextractinsightsfromvast
volumesofresearchdatasupply
chain
technology
is
helping
transform
how
we
work
and
live”,2024.mining,feasibilityBeyond
AI:thewiderdigitalinnovationlandscapeLeadersareexploringabroadsetoftechnologies
–butscalingremainsuneven.Theexcitementof
AIshouldnotobscurethevalueofothertechnologies,andindeedrespondentsshowedappetitefora
widerangeoftechnologieswithpotentialtoimproveefficiency,
innovation,cost,andcompliance
(Chart8).EmbracingAIandnewtechnologiesInnovationinaction:QuantumcomputingfordrugdiscoveryQuantumcomputingisbeingexplored
asa
futurecomplementtoclassical
high-performance
computing
in
early-stage
drug
discovery.
Its
primary
potentialliesinmolecular
simulationand
quantumchemistry,
where
quantum
methods
could,in
the
long
term,modelelectronic
structuresand
reactionmechanismswithhigher
accuracythan
classical
approaches.In
the
near
to
mid-term,most
applicationsrelyonhybrid
quantum–classicalapproaches,combiningclassicalsimulations,AI/ML
models,and
quantum-derived
features.
Theseapproachesaimtoimprovethequalityof
molecular
predictionsand
candidate
prioritization,ratherthanreplaceexistingcomputational
chemistryand
laboratoryworkflows.Whileoptimismfortechnologywaspositive,someresultsraise
potential
concerns.80%of
respondents
said
they
wereexploringimmersivetechnologies,
yetthishasbeenthecase
for
years.Thissuggestseithertheyarenotdeliveringashoped
–at
least
not
at
scale
–or
something
is
blockingprogress.Digitaltwinscouldbeasimilarstory.Inengineering,digital
twinshavealreadydeliveredsometransformativeoutcomes,
yet
in
life
sciences,75%are
still
only
at
the
piloting
stage,and
just9%at
the
deployment
stage.This
is
low
consideringthetechnologyhasprovenusecases,butnotoutoflinewith
otherindustries.When
it
comes
to
deploying
digital
technologies,AI
–
at86%
deployment
–seemstobesignificantlyaheadofthegame.Newertechnologies,includinghumanoidrobotsandquantum,were
on
the
agenda,with76and77%respectivelyexploringthese.It’stooearlyto
judgeprogressoneither,but
reassuringtoseefrontiertechnologieslikethesebeingtaken
seriously.Shiftingtoglobaloperatingmodels
andaccessingglobaltalentGlobaloperatingmodelsholdpromiseforallthreepriorities:increasedagility,faster
innovation,andcostreduction.Accessingglobaltalentpoolscanbakeinagilityandresilience,removingbottlenecksthatslowinnovationandproductioncausedbytalent
scarcityintraditionaloperatinglocations.Thistransformationisnotnew,butthedata
impliesachangeinapproach
–fromacost-cuttingexercisetoastrategicleverthatenablesflexibilityandtimescalereduction.Overhalfofcompanies(57%)alreadyoperatestrategicallyfocusedoffshore/remote
Centers
of
Excellence
and77%plan
to
increase
their
use.Such
Centers
of
Excellence
giveorganizationsacentralizedhubofspecializedexpertise
–withstandardizedbest
practices,optimizedprocessesandcutting-edgetechnologies
–thatsupporthigh-quality,high-productivitydeliveryatscale.76%already
right
shore
and
co-source
specific
engineering&operations
activities
–and62%plan
to
increase
this
approach
for
defined
work
packages
over
the
comingyears.Highlights83%intendtoincreaseperformance-based
outsourcing77%plantoexpandoffshoreCentersofExcellence
–ashifttowardmorestrategic
globalmodels76%already
outsource
engineering
or
R&D
activitiesOthersignsofamovetowardsmorestrategicglobaloperatingmodelsemergefromthedata.Forexample,
83%plan
to
increase
performance-based
outsourcing,
温馨提示
- 1. 本站所有资源如无特殊说明,都需要本地电脑安装OFFICE2007和PDF阅读器。图纸软件为CAD,CAXA,PROE,UG,SolidWorks等.压缩文件请下载最新的WinRAR软件解压。
- 2. 本站的文档不包含任何第三方提供的附件图纸等,如果需要附件,请联系上传者。文件的所有权益归上传用户所有。
- 3. 本站RAR压缩包中若带图纸,网页内容里面会有图纸预览,若没有图纸预览就没有图纸。
- 4. 未经权益所有人同意不得将文件中的内容挪作商业或盈利用途。
- 5. 人人文库网仅提供信息存储空间,仅对用户上传内容的表现方式做保护处理,对用户上传分享的文档内容本身不做任何修改或编辑,并不能对任何下载内容负责。
- 6. 下载文件中如有侵权或不适当内容,请与我们联系,我们立即纠正。
- 7. 本站不保证下载资源的准确性、安全性和完整性, 同时也不承担用户因使用这些下载资源对自己和他人造成任何形式的伤害或损失。
最新文档
- 2026年机械专业设计题库及参考答案
- 2026年十一月中旬助理医师资格考试临床助理医师测试模拟试卷(含答案)
- 2026年评标专家入库理论考试模拟题及答案
- 2026年外汇衍生品题库带答案
- 2026年CPR心肺复苏理论考试模拟题题库及参考答案
- 2026年急诊科停电应急演练在线模拟题(含答案)
- 2026年城市监察考试题库带答案
- 2026年全国企业安全生产知识竞赛复习题库带答案
- 2026年轮机操作技能考试题库及答案
- 2026年度河南省继续教育华医复习题库(含答案)
- 雨课堂学堂在线学堂云《机器学习实践(北京理工)》单元测试考核答案
- 2025版ICU患者PADIS管理指南课件
- 2026年中央一号文件解读:农业废弃物资源化利用
- 多功能中成药灭菌柜设备验证方案
- 露天矿山车辆安全培训课件
- 安徽省阜阳市2025-2026学年高一(上)期中物理试卷(A卷)(含答案)
- 2025年12月广西普通高中学业水平合格性考试物理真题试卷含详解
- 风电场发电功率智能预测建模流程和应用规范(征求意见稿)
- 江苏无锡2015-2024年中考满分作文125篇
- 口腔种植取模技术规范
- 肺叶切除术麻醉管理要点
评论
0/150
提交评论